Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 14:14:49.
doi: 10.1186/1471-2415-14-49.

The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients

Anil Vaidya  1 , Elio Borgonovi, Rod S Taylor, José-Alain Sahel, Stanislao Rizzo, Paulo Eduardo Stanga, Amit Kukreja, Peter Walter
Affiliations

The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients

Anil Vaidya et al. BMC Ophthalmol. .

Abstract

Background: Retinitis Pigmentosa (RP) is a hereditary genetic disease causing bilateral retinal degeneration. RP is a leading cause of blindness resulting in incurable visual impairment and drastic reduction in the Quality of life of the patients. Second Sight Medical Products Inc. developed Argus II, a retinal prosthesis system for treating RP. Argus II is the world's first ever-commercial implant intended to restore some vision in the blind patients. The objective of this study was to assess the cost-effectiveness of the Argus® II Retinal Prosthesis System (Argus II) in Retinitis Pigmentosa (RP) patients.

Method: A multi -state transition Markov model was developed to determine the cost-effectiveness of Argus II versus usual care in RP from the perspective of healthcare payer. A hypothetical cohort of 1000 RP patients aged 46 years followed up over a (lifetime) 25-year time horizon. Health outcomes were expressed as quality adjusted life years (QALYs) and direct healthcare costs expressed in 2012 €. Results are reported as incremental cost per ratios (ICERs) with outcomes and costs discounted at an annual rate of 3.5%.

Results: The ICER for Argus II was €14,603/QALY. Taking into account the uncertainty in model inputs the ICER was €14,482/QALY in the probabilistic analysis. In the scenarios of an assumption of no reduction on cost across model visual acuity states or a model time horizon as short as 10 years the ICER increased to €31,890/QALY and €49,769/QALY respectively.

Conclusion: This economic evaluation shows that Argus II is a cost-effective intervention compared to usual care of the RP patients. The lifetime analysis ICER for Argus II falls below the published societal willingness to pay of EuroZone countries.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Markov model.
Figure 2
Figure 2
Incremental cost-effectiveness plane.
Figure 3
Figure 3
Cost-effectiveness acceptability curves (CEACs).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sobaci G, Ozge G, Gundogan FC. Cone dysfunctions in retinitis pigmentosa with retinal nerve fiber layer thickening. Clin Ophthalmol. 2012;6:473–478. - PMC - PubMed
    1. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795–1809. doi: 10.1016/S0140-6736(06)69740-7. - DOI - PubMed
    1. Taylor HR. LXIII Edward Jackson memorial lecture: eye care: dollars and sense. Am J Ophthalmol. 2007;143(1):1–8. doi: 10.1016/j.ajo.2006.10.003. e1. - DOI - PubMed
    1. Hahm B-J, Shin Y-W, Shim E-J, Jeon HJ, Seo J-M, Chung H, Yu HG. Depression and the vision-related quality of life in patients with retinitis pigmentosa. Br J Ophthalmol. 2008;92(5):650–654. doi: 10.1136/bjo.2007.127092. - DOI - PubMed
    1. Winkler MS, Krieger GR, Divall MJ, Cisse G, Wielga M, Singer BH, Tanner M, Utzinger J. Untapped potential of health impact assessment. Bull World Health Organ. 2013;91(4):298–305. doi: 10.2471/BLT.12.112318. - DOI - PMC - PubMed

LinkOut - more resources

-